Zoetis Introduces Lenivia, a New Long-Acting Treatment for Canine Osteoarthritis Pain in Great Britain

Osteoarthritis is a common chronic condition in dogs, particularly as they age, necessitating effective pain control and tailored treatment strategies. Lenivia aims to simplify treatment schedules and enhance continuity of care due to its extended dosing interval.

Lenivia functions by targeting nerve growth factor (NGF), which plays a crucial role in pain signaling related to osteoarthritis. By binding to NGF, izenivetmab inhibits its action, mitigating the associated pain. Unlike other anti-NGF monoclonal antibodies, Lenivia attaches to a different site on the NGF molecule, which sets its mechanism apart from other products.

The development of Lenivia spanned approximately ten years, culminating in a pivotal European field study that evaluated the treatment over nine months. Results showed sustained reductions in osteoarthritis pain, with relief noticeable as early as Day 7 post-injection. Pain relief can last for up to three months.

Veterinarians interested in using Lenivia should consult the Summary of Product Characteristics (SPC) for details on approved indications, contraindications, precautions, and potential adverse effects.

The impact of osteoarthritis on canine health is significant, with estimates indicating that nearly 40% of dogs may suffer from the condition. Effective long-term management is critical as the prevalence of osteoarthritis increases with the aging canine population. Osteoarthritis not only affects mobility but also overall quality of life, underscoring the necessity for continuous pain management and regular treatment assessments.

Lenivia’s quarterly administration schedule may benefit both veterinary practices and pet owners by reducing the burden of frequent treatments while ensuring ongoing pain management. Tim Burgess, General Manager of Zoetis UK, noted that a longer dosing interval could aid in maintaining consistent care for dogs requiring ongoing treatment.

This new injectable option expands Zoetis's portfolio of therapies for canine osteoarthritis. As Lenivia becomes more widely available in Great Britain, Zoetis plans to support veterinary teams in integrating this product into their practices. Successful incorporation of Lenivia into treatment regimens will involve careful patient selection and adherence to the prescribing information, along with ongoing monitoring of treatment efficacy.

Overall, Lenivia offers veterinarians a valuable new tool in the management of chronic osteoarthritis pain in dogs, with its long-lasting effects promoting enhanced treatment adherence and improved quality of life for affected animals.

Source: Zoetis UK Ltd. Press release, "Zoetis Launches Lenivia® (izenivetmab injection) in Great Britain," September 24, 2026.